These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 28070724)
1. Identification of potential glutaminyl cyclase inhibitors from lead-like libraries by in silico and in vitro fragment-based screening. Szaszkó M; Hajdú I; Flachner B; Dobi K; Magyar C; Simon I; Lőrincz Z; Kapui Z; Pázmány T; Cseh S; Dormán G Mol Divers; 2017 Feb; 21(1):175-186. PubMed ID: 28070724 [TBL] [Abstract][Full Text] [Related]
2. Repurposing FDA-Approved Compounds for the Discovery of Glutaminyl Cyclase Inhibitors as Drugs Against Alzheimer's Disease. Xu C; Zou H; Yu X; Xie Y; Cai J; Shang Q; Ouyang N; Wang Y; Xu P; He Z; Wu H ChemistryOpen; 2021 Sep; 10(9):877-881. PubMed ID: 33377311 [TBL] [Abstract][Full Text] [Related]
3. Discovery of Potent Human Glutaminyl Cyclase Inhibitors as Anti-Alzheimer's Agents Based on Rational Design. Hoang VH; Tran PT; Cui M; Ngo VT; Ann J; Park J; Lee J; Choi K; Cho H; Kim H; Ha HJ; Hong HS; Choi S; Kim YH; Lee J J Med Chem; 2017 Mar; 60(6):2573-2590. PubMed ID: 28234463 [TBL] [Abstract][Full Text] [Related]
4. Inhibitory effect of flavonoids on human glutaminyl cyclase. Li M; Dong Y; Yu X; Zou Y; Zheng Y; Bu X; Quan J; He Z; Wu H Bioorg Med Chem; 2016 May; 24(10):2280-6. PubMed ID: 27061673 [TBL] [Abstract][Full Text] [Related]
5. Discovery of potential scaffolds for glutaminyl cyclase inhibitors: Virtual screening, synthesis, and evaluation. Zhou Q; Cai J; Qin F; Liu J; Li C; Xiong W; Wang Y; Xu C; Wu H Bioorg Med Chem; 2024 Jan; 97():117542. PubMed ID: 38104495 [TBL] [Abstract][Full Text] [Related]
6. Potent human glutaminyl cyclase inhibitors as potential anti-Alzheimer's agents: Structure-activity relationship study of Arg-mimetic region. Ngo VTH; Hoang VH; Tran PT; Ann J; Cui M; Park G; Choi S; Lee J; Kim H; Ha HJ; Choi K; Kim YH; Lee J Bioorg Med Chem; 2018 Mar; 26(5):1035-1049. PubMed ID: 29398442 [TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationship investigation of Phe-Arg mimetic region of human glutaminyl cyclase inhibitors. Ngo VTH; Hoang VH; Tran PT; Van Manh N; Ann J; Kim E; Cui M; Choi S; Lee J; Kim H; Ha HJ; Choi K; Kim YH; Lee J Bioorg Med Chem; 2018 Jul; 26(12):3133-3144. PubMed ID: 29705377 [TBL] [Abstract][Full Text] [Related]
8. Probing secondary glutaminyl cyclase (QC) inhibitor interactions applying an in silico-modeling/site-directed mutagenesis approach: implications for drug development. Koch B; Buchholz M; Wermann M; Heiser U; Schilling S; Demuth HU Chem Biol Drug Des; 2012 Dec; 80(6):937-46. PubMed ID: 22967026 [TBL] [Abstract][Full Text] [Related]
9. Identifying hQC Inhibitors of Alzheimer's Disease by Effective Customized Pharmacophore-Based Virtual Screening, Molecular Dynamic Simulation, and Binding Free Energy Analysis. Lin W; Zheng X; Fang D; Zhou S; Wu W; Zheng K Appl Biochem Biotechnol; 2019 Apr; 187(4):1173-1192. PubMed ID: 30187344 [TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationship of human glutaminyl cyclase inhibitors having an N-(5-methyl-1H-imidazol-1-yl)propyl thiourea template. Tran PT; Hoang VH; Thorat SA; Kim SE; Ann J; Chang YJ; Nam DW; Song H; Mook-Jung I; Lee J; Lee J Bioorg Med Chem; 2013 Jul; 21(13):3821-30. PubMed ID: 23643900 [TBL] [Abstract][Full Text] [Related]
11. Identification of B. anthracis N(5)-carboxyaminoimidazole ribonucleotide mutase (PurE) active site binding compounds via fragment library screening. Lei H; Jones C; Zhu T; Patel K; Wolf NM; Fung LW; Lee H; Johnson ME Bioorg Med Chem; 2016 Feb; 24(4):596-605. PubMed ID: 26740153 [TBL] [Abstract][Full Text] [Related]
12. Identification of imidazole-based small molecules to combat cognitive disability caused by Alzheimer's disease: A molecular docking and MD simulations based approach. Haque A; Alenezi KM; Abdul Rasheed MSM Comput Biol Chem; 2024 Oct; 112():108152. PubMed ID: 39038422 [TBL] [Abstract][Full Text] [Related]
13. Hsp90 inhibitors and drugs from fragment and virtual screening. Roughley S; Wright L; Brough P; Massey A; Hubbard RE Top Curr Chem; 2012; 317():61-82. PubMed ID: 21647838 [TBL] [Abstract][Full Text] [Related]
14. Discovery of highly potent human glutaminyl cyclase (QC) inhibitors as anti-Alzheimer's agents by the combination of pharmacophore-based and structure-based design. Van Manh N; Hoang VH; Ngo VTH; Ann J; Jang TH; Ha JH; Song JY; Ha HJ; Kim H; Kim YH; Lee J; Lee J Eur J Med Chem; 2021 Dec; 226():113819. PubMed ID: 34536669 [TBL] [Abstract][Full Text] [Related]
15. An overview of glutaminyl cyclase inhibitors for Alzheimer's disease. Coimbra JR; Sobral PJ; Santos AE; Moreira PI; Salvador JA Future Med Chem; 2019 Dec; 11(24):3179-3194. PubMed ID: 31838899 [TBL] [Abstract][Full Text] [Related]
16. Efficient search of chemical space: navigating from fragments to structurally diverse chemotypes. Wassermann AM; Kutchukian PS; Lounkine E; Luethi T; Hamon J; Bocker MT; Malik HA; Cowan-Jacob SW; Glick M J Med Chem; 2013 Nov; 56(21):8879-91. PubMed ID: 24117015 [TBL] [Abstract][Full Text] [Related]
17. Inhibitors for human glutaminyl cyclase by structure based design and bioisosteric replacement. Buchholz M; Hamann A; Aust S; Brandt W; Böhme L; Hoffmann T; Schilling S; Demuth HU; Heiser U J Med Chem; 2009 Nov; 52(22):7069-80. PubMed ID: 19863057 [TBL] [Abstract][Full Text] [Related]
19. The first potent inhibitors for human glutaminyl cyclase: synthesis and structure-activity relationship. Buchholz M; Heiser U; Schilling S; Niestroj AJ; Zunkel K; Demuth HU J Med Chem; 2006 Jan; 49(2):664-77. PubMed ID: 16420052 [TBL] [Abstract][Full Text] [Related]
20. A patent review of glutaminyl cyclase inhibitors (2004-present). Coimbra JRM; Salvador JAR Expert Opin Ther Pat; 2021 Sep; 31(9):809-836. PubMed ID: 33896339 [No Abstract] [Full Text] [Related] [Next] [New Search]